Prothena Corporation plc
PRTA
Key stats
- Open
- 8.70
- Day high
- 8.70
- Day low
- 8.22
- Previous close
- 8.73
- Volume
- 237.0K
- VWAP
- 8.29
- 52-week high
- 11.80
- 52-week low
- 7.73
- Market cap
- 448.28M
- Shares out
- 51.35M
- Employees
- 67
- Listed
- 2012
About Prothena Corporation plc
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
PHARMACEUTICAL PREPARATIONS · DUBLIN 2, L2 · prothena.com
Options · expiring Nov 20
Nov 12, 3:59 PM ET- Call open interest
- 1.2K
- Put open interest
- 1
- Put/call
- 0.00
- At-the-money IV
- 122.5%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 10 call | 0.05 | Nov 11, 3:58 PM | 17 | 42 | 138.6% |
| 9 call | 0.20 | Nov 2, 10:40 AM | 11 | 1.0K | 146.6% |
| 7 call | 1.96 | Sep 24, 3:48 PM | 5 | 5 | 420.4% |
| 8 call | 0.40 | Nov 12, 3:59 PM | 1 | 81 | 122.5% |
| 9 put | 0.82 | Sep 21, 11:23 AM | 1 | 1 | — |
| 6 call | — | — | 0 | 0 | 309.3% |
Quarterly results
Massive · Nov 5, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $620.0K | $1.01M | $51.08M | $21.0K |
| Gross profit | $620.0K | $1.01M | $51.08M | $21.0K |
| Operating income | −$18.82M | −$21.10M | $30.04M | −$24.20M |
| Net income | −$16.51M | −$18.58M | $32.72M | −$21.59M |
| Diluted EPS | -0.32 | -0.36 | 0.60 | -0.40 |
| Operating cash flow | −$11.96M | −$25.05M | $28.88M | −$23.31M |
| Assets | $283.52M | $302.58M | $349.89M | $326.80M |
| Liabilities | $14.68M | $15.69M | $37.28M | $46.33M |
| Equity | $268.84M | $286.89M | $312.62M | $280.47M |
Technicals
Massive · Nov 12, 2026- 50-day average8.57
- 200-day average9.18
- RSI (14 days)46.6
Short interest
Massive · Oct 30, 2026- Oct 30, 20267.91M shares · 15.7 days to cover
- Oct 15, 20267.94M shares · 13.3 days to cover
- Sep 30, 20268.01M shares · 13.8 days to cover
- Sep 15, 20268.54M shares · 26.5 days to cover
News coverage
No stories about Prothena Corporation plc right now.